| Title： | Diagnostic Criteria for Traditional Chinese Medicine Syndromes of Bone-related Adverse Events in Breast Cancer Endocrine Therapy |
| Edition： | Original |
| Classification： | Standard |
| Field： | Diagnosis |
| Countries and regions： | China |
| Guidelines users： | Physicians of traditional Chinese medicine, western medicine, and integrated traditional Chinese and western medicine |
| Evidence classification method： | Grading of recommendations assessment, development and evaluation（GRADE）. And considering the special nature of TCM syndromes and the importance of expert recognition, adjustments will be made in conjunction with the level of expert endorsement. |
| Development unit： | Shanghai Association of Traditional Chinese Medicine for Breast Diseases, and Longhua Hospital Affiliated with Shanghai University of Traditional Chinese Medicine. |
| Registration time: | 2024-09-07 |
| Registration number： | PREPARE-2024CN435 |
| Purpose of the guideline: | Breast cancer patients with positive hormone receptors account for about two-thirds of all patients in our country. Such patients should receive endocrine therapy, with common drugs represented by tamoxifen (TAM) and third-generation aromatase inhibitors (AI). The duration of endocrine therapy is 5 years, and some can be extended to 10 years. The survival of premenopausal patients with ovarian function suppression (OFS) combined with AI is also of concern. Adverse reactions related to postoperative endocrine therapy for breast cancer, especially bone adverse events, have attracted widespread attention. In response to symptoms such as bone and joint soreness, poor mobility, pain, and even fractures, traditional Chinese medicine has distinct therapeutic effects. The perfect integration of traditional Chinese medicine with modern endocrine therapy can exert their respective advantages, complement each other, and provide important help for improving compliance with endocrine therapy and enhancing the quality of life for patients. However, there are currently no standards discussing the diagnosis of traditional Chinese medicine syndromes for bone adverse events during endocrine therapy for breast cancer, and it is very important to clarify this standard under the guidance of the theory system of syndrome differentiation and treatment in traditional Chinese medicine. Formulate rigorous and standardized evidence-based medical evidence, standardize the traditional Chinese medicine syndrome standards for improving bone-related adverse events during the endocrine therapy period of breast cancer, and lay the foundation for standardized treatment plans for traditional Chinese medicine practitioners, Western medicine practitioners, and integrated medicine practitioners. |
Latest registration
